Improvement in Preexisting Multiple Sclerosis–Related Disability with Alemtuzumab

Moving from a paradigm of lessening worsening to promoting improvement

Alemtuzumab, a monoclonal antibody against CD52, is a licensed treatment for relapsing-remitting multiple sclerosis (MS). The phase III CARE-MS II study, was a randomized, rater-blinded, head-to-head, partially manufacturer-sponsored trial comparing alemtuzumab, dosed at 12 mg per day intravenously for 5 days and redosed 1 year later for 3 days, to subcutaneous interferon-beta-1a (SC INF-beta-1a) 44 µg three times weekly (NEJM JW Neurol Jan 2013 and Lancet 2012; 380:1829). Now, a secondary analysis of CARE-MS II examines prespecified and posthoc disability outcomes.

The new finding is that at 2 years, alemtuzumab-treated patients were more likely than interferon-treated patients to show improvement on the Expanded Disability Status Scale (ED…

Reviewing Author

Jeffrey M. Gelfand, MD

Disclosures

12/1/14I recently attended a trial investigator meeting as a sub-investigator for a clinical trial sponsored by Medimmune.

Jeffrey M. Gelfand, MD

Disclosures

12/1/14I recently attended a trial investigator meeting as a sub-investigator for a clinical trial sponsored by Medimmune.

Improvement in Preexisting Multiple Sclerosis–Related Disability with Alemtuzumab

Topics

Reviewing Author